Search / 104 results found

from
to
  • Updated

DURHAM, N.C., May 6, 2021 /PRNewswire/ -- Polarisqb is proud to add Dr. Ian Reynolds, a world renowned expert in pharmacology, as an advisor to the company. Dr. Ian Reynolds is an experienced pharmaceutical executive who has been recognized for his work in small molecule drug discovery and has helped a number ofacademic researchers translate into the world of biotech research and drug development.

  • Updated

WILMINGTON, N.C., May 5, 2021 /PRNewswire/ -- Isosceles Pharmaceuticals Inc. a biotechnology company dedicated to developing, commercializing, and marketing innovative non-opioid products for the treatment of mild to moderate pain and inflammatory diseases, today announced the appointment of William D. Humphries as its Chief Executive Officer. Mr. Humphries is a highly accomplished executive leader in the pharmaceutical industry with a proven track record leading several global pharmaceutical companies.

  • Updated

GREENVILLE, N.C., April 30, 2021 /PRNewswire/ -- Mayne Pharma announced today results from two studies showing treatment with NEXTSTELLIS® (3 mg drospirenone [DRSP] and 14.2 mg estetrol [E4] tablets) demonstrated contraceptive efficacy and excellent cycle control across subgroups, including age, body mass index (BMI)[1] and prior contraceptive use. NEXTSTELLIS is the first contraceptive pill containing E4, a new naturally occurring estrogen with a unique mechanism of action that offers potential advantages over other estrogens. The findings were presented at the 2021 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting, held virtually in the U.S. from April 30 – May 2.

  • Updated

NANTES, France and CARY, N.C., April 26, 2021 /PRNewswire/ -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) and Veloxis Pharmaceuticals Inc., a subsidiary of Asahi Kasei, today announced a global license agreement granting Veloxis Pharmaceuticals worldwide rights to develop, manufacture and commercialize FR104, a CD28 antagonist monoclonal antibody fragment, for all transplant indications. In parallel, OSE Immunotherapeutics retains all product rights to develop FR104 in autoimmune diseases. Through this license agreement, Veloxis plans to develop FR104 to provide a new therapeutic option for prophylaxis of organ rejection in patients receiving a solid organ transplant.